Futura Medical Provides Business Update, Announces Interim Results
The healthcare company announces board changes and a review of its business and commercial plans for its lead product Eroxon.
The healthcare company announces board changes and a review of its business and commercial plans for its lead product Eroxon.
The healthcare company provides an update on its recent share price movement, noting the increase but stating it knows of no specific reason for the rise.
The consumer healthcare group behind Eroxon® announces changes to its Board of Directors, with the CEO and Chair stepping down and an interim CEO being appointed.
The healthcare company announces its upcoming Annual General Meeting and the availability of its annual report.
The healthcare company has appointed a new broker to act as its sole broker and continue as Nominated Adviser.
The healthcare company reported its maiden profit and significant revenue growth, but warned of slower expansion and launch delays, impacting future performance expectations.
The healthcare company will announce its annual results and host investor presentations next month.
The healthcare company has appointed a new Non-executive Director with investment management experience.
The healthcare company reported strong FY24 results but drastically lowered FY25 expectations due to slower product adoption. A shift from anticipated profits to projected losses in FY25 has overshadowed the positive performance.
The healthcare company reports successful completion of a study for its women's sexual dysfunction treatment, paving the way for further development.